Search results
Results From The WOW.Com Content Network
The Descartes Systems Group Inc. (commonly referred to as Descartes) is a Canadian multinational technology company specializing in logistics software, supply chain management software, and cloud -based services for logistics businesses. Descartes is perhaps best known for its abrupt and unexpected turnaround in the mid-2000s after coming close ...
Website. www.datamyne.com. Datamyne was a privately held corporation that provides access to a searchable database of import-export trade of 50 countries across five continents. The company was acquired by Descartes Systems Group in December 2016. The purchase price for the acquisition was approximately US$52.7 million in cash.
Descartes Visual Compliance (USA) LLC (dba "Visual Compliance") is a technology company that specializes in global trade compliance solutions [buzzword], in particular applications that allow thousands of subscribers located in over 100 countries to screen for denied and restricted parties. The company was acquired by Descartes Systems Group in ...
Descartes Systems Group (NAS: DSGX) reported earnings on May 31. Here are the numbers you need to know. The 10-second takeawayFor the quarter ended April 30 (Q1), Descartes Systems Group met ...
Need help? Call us! 800-290-4726 Login / Join. Mail
Descartes Systems Group (NAS: DSGX) is expected to report Q1 earnings on May 30. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year ...
www.antoniodamasio.com. Antonio Damasio (Portuguese: António Damásio) is a Portuguese neuroscientist. He is currently the David Dornsife Chair in Neuroscience, as well as Professor of Psychology, Philosophy, and Neurology, at the University of Southern California, and, additionally, an adjunct professor at the Salk Institute. [1]
Relative to Descartes-08, Descartes-15 has been observed to achieve an approximately ten-fold increase in CAR expression and selective target-specific killing in preclinical studies. The Phase 1 dose escalation trial (NCT06304636) will assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma.